Table 1.
Baseline patient characteristics by drug use (n = 242).
| Characteristics | No. of Patients (%) | p Value | ||
|---|---|---|---|---|
| PPI Use (n = 110) | H2RA Use (n = 33) | Non-Acid Suppressant Use (n = 99) | ||
| Age category (years) | ||||
| <50 | 4 (3.63) | 5 (15.15) | 6 (6.06) | 0.564 |
| 50–60 | 12 (10.91) | 4 (12.13) | 19 (19.19) | |
| 60–70 | 37 (33.64) | 11 (33.33) | 37 (37.37) | |
| 70–80 | 46 (41.82) | 13 (39.39) | 35 (35.35) | |
| ≥80 | 11 (10.00) | 0 | 2 (2.02) | |
| Sex | ||||
| Female | 49 (44.55) | 20 (60.61) | 44 (44.44) | 0.202 |
| Male | 61 (55.45) | 13 (39.39) | 55 (55.56) | |
| NSAID use | 51 (46.36) | 17 (51.52) | 24 (24.24) | <0.001 |
| Sydney System Factor Score | ||||
| Atrophy antrum | 1.221 ± 0.778 | 1.160 ± 0.898 | 0.986 ± 0.778 | 0.254 |
| corpus | 0.755 ± 0.860 | 0.429 ± 0.898 | 0.613 ± 0.751 | 0.140 |
| Metaplasia antrum | 0.633 ± 0.889 | 0.515 ± 0.667 | 0.443 ± 0.667 | 0.411 |
| corpus | 0.284 ± 0.708 | 0.156 ± 0.448 | 0.122 ± 0.503 | 0.116 |
| Mononuclear cell antrum | 1.211 ± 0.639 | 1.303 ± 0.684 | 1.243 ± 0.648 | 0.713 |
| corpus | 1.211 ± 0.759 | 1.273 ± 0.674 | 1.102 ± 0.681 | 0.428 |
| Neutrophil antrum | 0.352 ± 0.646 | 0.455 ± 0.833 | 0.427 ± 0.778 | 0.925 |
| corpus | 0.444 ± 0.777 | 0.424 ± 0.708 | 0.433 ± 0.776 | 0.947 |
| H. pylori antrum | 0.389 ± 0.783 | 0.273 ± 0.626 | 0.333 ± 0.660 | 0.769 |
| corpus | 0.333 ± 0.641 | 0.424 ± 0.969 | 0.443 ± 0.841 | 0.826 |
Abbreviations: PPI, proton pump inhibitor; H2RA, histamine 2 receptor antagonist; NSAID, non-steroidal anti-inflammatory drug. Bold, statistical significance.